Differences in lipid parameters among statins treated patients with coronary arteriosclerosis - a pilot study

European Journal of Lipid Science and Technology

Volumn 114, Issue 8, 2012, Pages 869-874

  Burchardt, Pawel ^a   Zurawski, Jakub ^a   Kubacki, Tomasz ^a   Zuchowski, Bartosz ^a   Wysocki, Henryk ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

ApoB100 ratio; Coronary artery disease; Total cholesterol

Indexed keywords

EID: 84863733585     PISSN: 14387697     EISSN: 14389312     Source Type: Journal    
DOI: 10.1002/ejlt.201100260     Document Type: Article

References (19)

1. Kastelein, J. P., Van der Steeg, W. A., Holme, I., Gaffney, M. et al., Lipids, apoliproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008, 117, 3002- 3009.
2. Harper, C. R., Jacobson, T. A., Using apolipoprotein B to manage dyslipidemic patients: Time for a change? Mayo Clin. Proc. 2010, 85, 440- 445.
3. Sniderman, A., Targets for LDL-lowering therapy. Curr. Opin. Lipidol. 2009, 20, 282- 287.
4. Sniderman, A., Williams, K., Cobbaert, C., ApoB versus non-HDL-C: What to do when they disagree. Curr. Atheroscler. Rep. 2009, 11, 358- 363.
5. Walldius, G., Jungner, I., The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J. Inter. Med. 2006, 259, 493- 519.
6. Su, W., Campos, H., Judge, H., Walsh B. W., Sachs F. M., Metabolism of apo(a) and apoB100 of lipoprotein(a) in women: Effect of postmenopausal estrogen replacement. J. Clin. Endocrinol. Metab. 1998, 83, 3267- 3276, DOI: 10.1210/jc.83.9.3267.
7. Islam, S., Gutin, B., Manos, T., Smith, C., Treiber, F., LDL cholesterol/apolipoprotein B-100 ratio: Interaction of family history of premature atherosclerotic coronary artery disease with race and gender in 7 to 11 year olds. Pediatrics 1994, 94, 494- 499.
8. Lavie, C. J., Milani, R. V., O'Keefe, J. H., Statin wars: Emphasis on potency vs. event reduction and safety. Mayo Clin. Proc. 2007, 82, 539- 542.
9. Nakamura, T., Obata, J., Hirano, M., Kitta, Y. et al., Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 2011, 218, 163- 167.
10. Ramjee, V., Sperling, L. S., Jacobson, T. A., Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification. Do the math. JACC 2011, 58, 457- 463.
11. Milani, R. V., Lavie, C. J., Another step forward in refining risk stratification. Moving past low-density lipoprotein cholesterol. JACC 2011, 58, 464- 466.
12. Burchardt, P., Wysocki, H., Is the regression of atherosclerosis only possible by lowering LDL levels and is this sufficient to reduce the tendency of these lipoproteins to oxidative modification? Kardiol. Pol. 2011, 69, 834- 837.
13. Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., Buring, J. E., Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294, 326- 333.
14. Ouguerrram, K., Chetiveaux, M., Zair, Y., Costet, P. et al., Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK. Arterioscler. Thromb. Vas. Biol. 2004; 24, 1- 6.
15. Blom, D. J., O'Neill, F. H., Marais, A. D., Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations. Clin. Chem. 2005, 51, 904- 907.
16. Bilz, S., Wagner, S., Schmitz, M., Bedynek, A. et al., Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J. Lipid Res. 2004, 45, 174- 185.
17. Qin, B., Anderson, R. A., Adeli, K., Tumor necrosis factor-a directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294, G1120- G1129.
18. Vandermeersch, A., Ameye, S., Puype, D., Petitjean, D. et al., Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment. Clin. Chim. Acta 2010, 411, 1361- 1366.
19. Albersa, J. J., Kennedya, H., Marcovina, S. M., Evaluation of a new homogenous method for detection of small dense LDL cholesterol: Comparison with the LDL cholesterol profile obtained by density gradient ultracentrifugation. Clin. Chim. Acta 2011, 412, 556- 556.